510(k) K260714

MammoScreen® (5) by Therapixel — Product Code QDQ

K260714 is an FDA 510(k) premarket notification submitted by Therapixel for the device "MammoScreen® (5)". The FDA issued a decision of Substantially Equivalent on Jun 26, 2026. The device falls under product code QDQ (Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer), a Class II device regulated under 21 CFR 892.2090. Therapixel has 6 other 510(k) clearances on record.

Clearance details

Decision
SESE (Substantially Equivalent)
Decision Date
Jun 26, 2026
Date Received
Mar 5, 2026
Clearance Type
Special
Expedited Review
No
Third Party Review
No

Device classification

Device Name
Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer
Device Class
Class II
Regulation Number
892.2090
Review Panel
RA
Submission Type
510(k)

A radiological computer assisted detection and diagnostic software for suspected lesions is an image processing device intended to aid in the detection, localization, and characterization of lesions suspicious for cancer on acquired medical images (e.g., mammography , MR, CT, ultrasound, radiography). The device detects, identifies and characterizes lesions suspicious for cancer based on features or information extracted from the images, and may provide information about the presence, location, and characteristics of the lesion to the user. Primary diagnostic and patient management decisions are made by the clinical user.

Need the full FDA record for Therapixel? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: FDA 510(k) database entry for K260714. Report a data issue: hello@regdatalab.com.